NBC Securities Inc. Boosts Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

NBC Securities Inc. grew its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 109,021.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 55,652 shares of the company's stock after acquiring an additional 55,601 shares during the period. NBC Securities Inc.'s holdings in Takeda Pharmaceutical were worth $827,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of TAK. Blair William & Co. IL raised its position in shares of Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after buying an additional 913 shares during the last quarter. Vise Technologies Inc. raised its holdings in shares of Takeda Pharmaceutical by 3.1% during the fourth quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock worth $459,000 after acquiring an additional 1,026 shares during the period. Sage Rhino Capital LLC raised its stake in shares of Takeda Pharmaceutical by 14.9% during the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock worth $157,000 after purchasing an additional 1,538 shares in the last quarter. Vident Advisory LLC lifted its holdings in Takeda Pharmaceutical by 13.5% during the 4th quarter. Vident Advisory LLC now owns 13,606 shares of the company's stock valued at $180,000 after purchasing an additional 1,616 shares during the last quarter. Finally, OLD Mission Capital LLC increased its position in Takeda Pharmaceutical by 13.7% during the 4th quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock worth $185,000 after buying an additional 1,687 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of TAK traded down $0.03 during trading hours on Friday, reaching $14.97. 1,625,742 shares of the company's stock traded hands, compared to its average volume of 1,942,507. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.43. The firm's 50 day simple moving average is $14.66 and its 200-day simple moving average is $14.10. The stock has a market cap of $47.62 billion, a PE ratio of 37.41, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The business had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.